December 20, 2016
January 24, 2017
Ongoing and increased investment in high-quality demonstration projects and evaluations is essential to learning more about the conditions under which Project ECHO—a telementoring program—works and fails, and about its potential for improving health care delivery and health outcomes. Read why...
Unlike other plans, the Price plan is not a comprehensive alternative vision for overall health care market reform, but instead, is largely limited to replacing the individual and small group reforms.
January 24, 2017 | Following the ACA
Workplace programs founded on a strong culture of health can positively influence workers’ health and well-being, and do so in a practical, ethical, and legal manner.
On January 20, 2017, Donald Trump was sworn in as President of the United States. True to his word, on his first day in office he issued an executive order addressing the Affordable Care Act. It may not be, however, all that his supporters expected.
Two ideas are surfacing in Republican plans to replace the Affordable Care Act that should be examined—setting a goal of “universal access” rather than “universal coverage” and shifting responsibility for ACA replacement to the states.
How does Grantmakers In Health—an association of health foundations and corporate-giving programs—plan to help funders understand, and respond to, significant expected changes in public policies and programs that affect the communities they serve?
All too often, criticisms of CBO’s methods are motivated by a misunderstanding of what CBO can and cannot be expected to do. As we engage in a new round of health policy debate, it is vital to examine CBO's role in the legislative process.
American systems of oral and systemic health---training, licensure, service delivery, and insurance---continue to operate in parallel. A growing evidence base points to the cost and quality shortfalls associated with having separate systems treat the same person.
Health Affairs Web First: US Six-Month Drug Market Exclusivity Extensions Could Yield Nearly $100 Million
A new study, released by Health Affairs as a Web First, analyzed the thirteen supplemental applications approved by the FDA that earned rare disease status from 2005 through 2010 to estimate the costs of the clinical trials and potential economic gain arising from a six-month exclusivity extension.
January 18, 2017 | Elsewhere@ Health Affairs
In this post, we’ll take a look at the possible advantages of allowing interstate insurance sales, as well as the reasons opponents say such a policy simply won’t work.